Fulfilling the Mission, Establishing Quality, [Reinovax Biologics] Keeps Original Aspiration and Persistent Ingenuity.

The 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) independently developed by Shanghai Reinovax Biologics initiated the phase I clinical trial for infants and toddlers on April 26th.

Today, People's Daily Health Client and Vaccine Circle jointly released a special report titled " Launching of Phase II trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Reinovax Biologics".

24-valent pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as PCV24), developed by Shanghai Reinovax Biologics with own intellectual property, was initiated Phase I clinical trial in Zhenjiang, Jiangsu province on November 16.